Patents Assigned to HK Pharmaceuticals, Inc.
  • Patent number: 7091046
    Abstract: A system for analyzing expression levels and activity of a plurality of proteins is provided. A bio-displayed polypeptide binding component associated with a predetermined marker is used to bind the proteins of interest. The predetermined marker components are then amplified and detected in a high throughput manner.
    Type: Grant
    Filed: December 11, 2001
    Date of Patent: August 15, 2006
    Assignee: HK Pharmaceuticals, Inc.
    Inventor: Joseph A. Monforte
  • Patent number: 6828435
    Abstract: The use of protection schemes and solid phase synthesis reactions to generate molecules of core structure M, which have a plurality of moieties, each of which can be individually deprotected or subsequently derivatized are provided. In one process, M is a multifunctional low molecular weight compound, such as a saccharide, aminosugar, deoxysugar, nucleoside, nucleotide, coenzyme, amino acid, lipid, steroid, vitamin, hormone, alkaloid, or small molecule drug. In another process, M is an oligomeric compound, such as an oligosaccharide, oligonucleotide, peptide or protein.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: December 7, 2004
    Assignee: HK Pharmaceuticals, Inc.
    Inventors: Hubert Koster, Eckart Leikauf
  • Publication number: 20040209255
    Abstract: Gradient arrays for the analysis of biomolecules are provided. In particular, arrays and methods are provided for analyzing complex protein mixtures, such as the proteome. The arrays provide bifunctional reagents that allow for the separation and isolation of complex protein mixtures. Automated instruments for performing the methods are also provided.
    Type: Application
    Filed: March 11, 2003
    Publication date: October 21, 2004
    Applicant: HK Pharmaceuticals, Inc.
    Inventors: Hubert Koster, Mikhail S. Shchepinov, Daniel P. Little
  • Patent number: 6803194
    Abstract: Double stranded DNAs, expression vectors and methods for their use are provided in which the intracellular expression of the double stranded DNAs is used to alter the phenotype of a target cell so that the function of a target nucleic acid that includes a nucleotide sequence encoding a motif of interest can be determined using a combinatorial ribozyme library. The members of the library are catalytic RNAs that disrupt the expression of the transcription product of the target nucleic acid. Disruption of transcription product expression results in an altered cell phenotype which is used to determine the function of the target nucleic acid. The specific phenotype or response may be associated with normal cellular processes, or it may contribute to the generation of pathogenesis involved in disease development. The compositions find use in high-throughput screens to assign gene functions.
    Type: Grant
    Filed: August 9, 2000
    Date of Patent: October 12, 2004
    Assignee: HK Pharmaceuticals, Inc.
    Inventors: James G. Keck, Justin G. P. Wong